Revenue grew 21.8% YoY to 18,796 million, but gross margin and operating EBITDA margin declined due to lower private label sales and higher expenses. Diagnostics segment delivered strong revenue and EBITDA growth, while 146 new stores were added and capex remained below plan.Original document: MedP…
Revenue grew 21.8% YoY to 18,796 million, but gross margin and operating EBITDA margin declined due to lower private label sales and higher expenses. Diagnostics segment delivered strong revenue and EBITDA growth, while 146 new stores were added and capex remained below plan.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
